Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
Metrics | Range | Conclusion |
---|---|---|
Selected LTM Pb Multiple | 2.3x - 2.5x | 2.4x |
Historical Pb Multiple | 0.9x - 4.6x | 2.8x |
Fair Value | $1.39 - $1.54 | $1.46 |
Upside | -40.8% - -34.6% | -37.7% |
Benchmarks | - | Full Ticker |
Dyadic International, Inc. | - | NasdaqCM:DYAI |
Onconetix, Inc. | - | NasdaqCM:ONCO |
Geron Corporation | - | NasdaqGS:GERN |
Arcturus Therapeutics Holdings Inc. | - | NasdaqGM:ARCT |
Ainos, Inc. | - | NasdaqCM:AIMD |
Spero Therapeutics, Inc. | - | NasdaqGS:SPRO |
Select Price / Book Ratio | ||||||||
Benchmark Companies | ||||||||
DYAI | ONCO | GERN | ARCT | AIMD | SPRO | |||
NasdaqCM:DYAI | NasdaqCM:ONCO | NasdaqGS:GERN | NasdaqGM:ARCT | NasdaqCM:AIMD | NasdaqGS:SPRO | |||
Historical Net Income Growth | ||||||||
5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
Latest Twelve Months | 25.8% | -25.9% | 31.0% | 36.4% | -1.9% | -398.1% | ||
Historical Net Income Profit Margin | ||||||||
5 Year Average Margin | -386.3% | -13605.6% | -23165.6% | -541.3% | -12542.7% | -383.6% | ||
Prior Fiscal Year | -234.4% | -63986.5% | -77690.7% | -17.8% | -11277.0% | 22.0% | ||
Latest Fiscal Year | -166.2% | -2333.4% | -226.7% | -53.1% | -71702.3% | -142.9% | ||
Latest Twelve Months | -163.9% | -2986.3% | -119.5% | -47.5% | -13967.4% | -156.5% | ||
Return on Equity | ||||||||
5 Year Average Margin | -73.9% | -395.0% | -70.1% | -33.2% | -314.3% | -61.4% | ||
Prior Fiscal Year | -80.1% | -334.2% | -112.3% | -10.8% | -46.6% | 24.9% | ||
Latest Twelve Months | -214.3% | -2879.9% | -45.3% | -27.4% | -82.9% | -107.3% | ||
Next Fiscal Year | 677.6% | 222.3% | -34.4% | -46.0% | #NUM! | -261.9% | ||
Two Fiscal Years Forward | 73.6% | 80.6% | -19.3% | -59.5% | 0.0% | 180.8% | ||
Current Trading Multiples | ||||||||
Price / LTM Sales | 9.5x | 1.0x | 7.0x | 2.8x | 101.7x | 2.9x | ||
Price / LTM EPS | -5.8x | 0.0x | -5.9x | -5.9x | -0.7x | -1.9x | ||
Price / Book | 36.5x | 0.5x | 3.0x | 1.7x | 0.8x | 3.9x | ||
Price / Fwd Book | -7.4x | 0.0x | 4.1x | 2.7x | 0.7x | -21.3x | ||
Low | Mid | High | ||||||
Benchmark P/B Ratio | 0.5x | 1.7x | 36.5x | |||||
Historical P/B Ratio | 0.9x | 2.8x | 4.6x | |||||
Selected P/B Multiple | 2.3x | 2.4x | 2.5x | |||||
(x) Book Value | 34 | 34 | 34 |
Equity Value | |||||||
Benchmark Companies | |||||||
(in millions) | DYAI | ONCO | GERN | ARCT | AIMD | SPRO | |
Value of Common Equity | 34 | 2 | 815 | 405 | 11 | 131 | |
(/) Shares Outstanding | 30.1 | 0.5 | 636.9 | 27.1 | 4.2 | 55.9 | |
Implied Stock Price | 1.12 | 3.61 | 1.28 | 14.95 | 2.60 | 2.35 | |
FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
Implied Stock Price (Trading Cur) | 1.12 | 3.61 | 1.28 | 14.95 | 2.60 | 2.35 | |
Trading Currency | USD | USD | USD | USD | USD | USD | |
FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |